DCB (N=15)	NDB (N=9)	P-value
Gender
Female	5 (33.3%)	2 (22.2%)	0.908
Male	10 (66.7%)	7 (77.8%)
Age (years)
>70	7 (46.7%)	1 (11.1%)	0.124
51-60	2 (13.3%)	2 (22.2%)
61-70	6 (40.0%)	4 (44.4%)
<51	0 (0%)	2 (22.2%)
Objective response
PR	9 (60.0%)	1 (11.1%)	0.00103
SD	6 (40.0%)	2 (22.2%)
PD	0 (0%)	6 (66.7%)
Clinical stage
IIB	1 (6.7%)	0 (0%)	0.139
IIIA	3 (20.0%)	0 (0%)
IV	3 (20.0%)	0 (0%)
IVA	8 (53.3%)	8 (88.9%)
IVB	0 (0%)	1 (11.1%)
PFS
>6	15 (100%)	0 (0%)	<0.001
<6	0 (0%)	9 (100%)
PFS status
0	5 (33.3%)	0 (0%)	0.153
1	10 (66.7%)	9 (100%)
OS
>60	2 (13.3%)	2 (22.2%)	0.527
12-24	5 (33.3%)	4 (44.4%)
24-36	5 (33.3%)	2 (22.2%)
36-48	2 (13.3%)	0 (0%)
48-60	1 (6.7%)	0 (0%)
<12	0 (0%)	1 (11.1%)
OS status
0	10 (66.7%)	6 (66.7%)	1
1	5 (33.3%)	3 (33.3%)
Drug type
Camrelizumab	4 (26.7%)	0 (0%)	0.133
KN046	2 (13.3%)	5 (55.6%)
Pembrolizumab	2 (13.3%)	1 (11.1%)
Sintilimab	2 (13.3%)	0 (0%)
Tislelizumab	5 (33.3%)	3 (33.3%)